Cholinesterases (ChEs) show increased activities in patients with Alzheimer’s disease, and remain one of the main therapeutic targets for treatment of this neurodegenerative disorder. This evidence concerns the gene BCHE and early-onset autosomal dominant Alzheimer disease.